Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7833138 | 0.90 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL7829784 | 0.89 | AGTR1 (0.40) | AGTR1AGTR2 | |
| SCHEMBL7832823 | 0.89 | AGTR1 (0.41) | AGTR1AGTR2 | |
| SCHEMBL7830155 | 0.88 | AGTR1 (0.51) | AGTR1AGTR2 | |
| SCHEMBL7828858 | 0.87 | AGTR1 (0.41) | AGTR1AGTR2 | |
| SCHEMBL7826869 | 0.87 | AGTR1 (0.43) | AGTR1AGTR2 | |
| SCHEMBL9530971 | 0.86 | AGTR1 (0.38) | AGTR1AGTR2 | |
| SCHEMBL7819287 | 0.86 | AGTR1 (0.57) | AGTR1AGTR2 | |
| SCHEMBL7831140 | 0.86 | AGTR1 (0.44) | AGTR1AGTR2 | |
| SCHEMBL7829568 | 0.86 | AGTR1 (0.43) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010020100-A1 | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders | G.D. SEARLE & CO. (US) | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020100-A1 | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders | NR3C2, AGTR1, PAH | AGTR1 2/4885AGTR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.